Press Releases

Global Revenue Of Fetal Monitoring And Diagnosis To Reach Nearly $8 Billion In 2016

August 24, 2011

Additional Reports


Wellesley, Mass. – In a recent release, FETAL MONITORING, DIAGNOSTICS AND PREDICTIVE TESTS (HLC089A) from BCC Research (, global revenues for fetal monitoring and diagnosis should reach $6.4 billion 2011. That value is projected to reach nearly $8 billion in 2016, after increasing at a five-year compound annual growth rate (CAGR) of 4.4%.

Fetal monitoring and diagnostics can be broken down into three segments – prenatal diagnosis, fetal monitoring, and neonatal monitoring.

In 2011, the prenatal diagnosis segment is expected to be worth $5.5 billion, and in 2016 that value is expected to reach $6.8 billion, yielding a CAGR of 4.3%.

The fetal monitoring segment should account for nearly $737 million in 2011, and in 2016 that value is expected to be $902 million, after increasing at a CAGR of 4.1%.

The neonatal monitoring segment, valued at $148 million for 2011, should reach $227 million in 2016, a CAGR of 8.9%.

Fetal monitoring, which entails the non-stress testing of a fetus’s various bodily parameters, is now the standard of care in most modern obstetric clinics and hospitals. The rising number of high-risk pregnancies is placing greater demands of advanced fetal-maternal monitoring during both the antepartum and intrapartum delivery of care during pregnancy. 

This study was conducted to provide vital and detailed information regarding fetal and neonatal monitoring and diagnosing. This industry is experiencing growth, as the concept of “fetus as a patient” has changed the entire industry. Technological advancements have made it possible to access and monitor the fetus.

Advanced maternal age and the development of innovative, safe, and noninvasive prenatal diagnostic technologies, combined with the increasing awareness of expectant mothers and medical reimbursements, are the driving forces for the market.

The report will be of interest to a variety of readers; specifically, it will be most useful to clinicians, physicians, the pharmaceutical and biopharmaceutical industries, hospitals, and research institutions.

To Contact us, click here  help

Source: BCC Research

Fetal Monitoring, Diagnostics and Predictive Tests( HLC089A )
Publish Date: Apr 2011    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: as the source and publisher. Thank you.